Wat is de prijs voor Brii Biosciences Limited (2137)

Het prijs van Brii Biosciences Limited (2137) is $0.12984512

Wat is de marktkapitalisatie voor Brii Biosciences Limited (2137)

Marktkapitalisatie voorBrii Biosciences Limited (2137) is $93.64M

Brii Biosciences Limited (2137) Operationele Marge

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.

Jaar	Operationele Marge	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Operationele Marge

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Operationele Marge	Verschil in operationele marge	Land
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Moderna, Inc. MRNA.US	-149.01%	-	US
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH

Bedrijf

Operationele Marge

Verschil in operationele marge

Land